Retrotransposons tune immune reactivity in differentiated cells because when 
Introduction
Transposable elements (TEs) are mobile genetic elements aptly named "controlling elements" by Barbara McClintock in the 1950s because of their ability to control cellular genes [1] . Since their discovery, the advancement of genome sequencing and bioinformatics technologies has led to the identification of a huge number of TE families, the functions of which are now being unraveled.
Retrotransposons are particularly relevant TEs because they can replicate through an RNA intermediate, allowing them to insert new DNA copies of themselves into the genome. This has enabled them to accumulate over millions of years and they now comprise more than half of the human genome [2] . Over time, deleterious insertions are negatively selected while those beneficial to the host become co-opted and fixed in the genome [3] . Co-opted retrotransposons are often from the endogenous retrovirus (ERV) class, which dates back hundreds of millions of years [4] . Although retrotransposons are overall beneficial as a driving force behind the evolution of new genes and non-coding DNA [5, 6] , they can also compromise genome and transcriptome integrity [7] . A multitude of epigenetic pathways, therefore, act in early development to constrain their transcription and some of these strategies remain active in differentiated cells.
Epigenetics refers to modifications on chromatin, rather than DNA sequence alterations, which lead to heritable effects on gene expression. Chromatin is subject to histone modifications and cytosine methylation and distinct epigenetic marks are associated with an active and silent gene expression state. For example, acetylation of histone 3 at the lysine residue at position 27 (H3K27ac) is a chromatin signature associated with active genes and enhancers [8] , whereas trimethylation of histone 3 at the lysine at position 9 (H3K9me3) correlates with heterochromatin and gene silencing [9] [10] [11] . Retrotransposons direct both genetic and epigenetic heritable traits because they can integrate into our genome in the germ line and orchestrate epigenetic alterations through the recruitment of transcription factors to their regulatory elements [12] .
Since half of the human genome is derived from retrotransposons, it can be viewed as non-self. Although most human retrotransposons are no longer mobile, expression of their nucleic acids and proteins can lead to the formation of pathogen-associated molecular patterns (PAMPs) and antigens that we refer to here as "neo-antigens" that could potentially elicit an immunological response.
Retrotransposons, are therefore situated at the interface of immune reactivity; when enriched in silent chromatin they are transcriptionally inactive and immune masked, whereas when expressed they may trigger innate and adaptive immunity [13] [14] [15] . In this review, we will discuss the mechanisms in place to maintain retrotransposons silent in differentiated cells and the implications of these pathways. We will focus here on chromatin readers, writers and erasers and the KAP1 and KRAB-ZNF system. The role of small RNAs, while important, is beyond the scope of this review and we direct the reader to a recent review covering this topic [16] .
Epigenetic pathways constraining retrotransposons
Epigenetic silencing of retrotransposons takes place in early embryos and in differentiated tissues, epigenetic states link back to patterns established during development [17] . The identification of factors that maintain repression in postembryonic tissues and how dynamic chromatin marks are in differentiated cell types is a fascinating and emerging area of research. Moreover, existing work relies largely on mouse models so it will be crucial to establish parallels in human cells, where the precise retrotransposons, their activity and their coevolution patterns with genes are distinct [18] .
Chromatin readers, writers and erasers
Chromatin-associated proteins induce epigenetic changes to either histones or 
Implications for immune regulation
ERVs have been implicated in multiple cancers and autoimmune diseases, including ovarian and breast cancer, systemic lupus erythematosus and multiple sclerosis [64, 65] . There is some convincing evidence that ERVs can play a causative role in cancer when their LTRs escape epigenetic repression [66] and interestingly, this involves mainly primate-specific ERVs [67] . For example, cryptic enhancers and promoters that reside within ERVs can drive expression of oncogenes [66, 68] .
ERVs regulate the immune system in several ways. For example, double stranded RNA (dsRNA) produced from retrotransposons, following treatment of cancer cells with DNA methyltransferase inhibitors activates interferon through MDA5, MAVS and IRF7 [13, 14] . Cytoplasmic DNA resulting from reverse transcription also serves as an additional PAMP because it is detected by the cytosolic DNA sensor cGAS to activate type I interferon through STING [63, [69] [70] [71] [72] . Likewise, Toll-like receptors contribute to ERV nucleic acid sensing [73] . Mutations within genes involved in nucleic acid metabolism including TREX1 are associated with autoimmune diseases [74] , although such factors block classes of retrotransposons that are constitutively transcribed rather than those embedded within silent chromatin. In addition to innate immunity, ERVs can stimulate adaptive immunity too because their encoded gene products, which are necessary for their mobilization are subject to standard antigen processing and presentation pathways. For example, tumour-associated antigens (TAAs) can be derived from HERV-K envelope protein [75] . Such neo-antigens can evoke adaptive T cell and antibody responses [76] 
Concluding remarks
While it was previously thought that histone marks are primarily required to silence retrotransposons only early in development [10, 50, 78, 79] , where DNA methylation is reprogrammed [80, 81] , recent evidence has led to a new paradigm whereby diverse epigenetic modifiers exert continuous roles in adult tissues. Here we discuss evidence that SETDB1, DNMTs, HP1, HSP90, the NuRD complex and potentially KAP1 and KRAB-ZNFs are some of these factors.
Importantly, most of these regulators have only been studied in mouse models so far. A future understanding of the pathways operating in adult human tissues is essential for the development of innovative drugs. Targeted epigenetic modulation might prove a potent tool in the future to reactivate certain retrotransposons so that their nucleic acids and proteins could serve as natural PAMPs to signal danger to their host. Such drugs may be valuable to stimulate immunosurveillance in cancer patients in which immune activation pathways may be subdued or could be used in conjunction with standard vaccines in place of an adjuvant. Caution should be applied, however, to prevent unwanted effects of reactivated ERVs on the genome or transcriptome. 
